Advertisement
UK markets close in 6 hours 52 minutes
  • FTSE 100

    8,109.18
    +30.32 (+0.38%)
     
  • FTSE 250

    19,801.35
    +199.37 (+1.02%)
     
  • AIM

    755.95
    +2.83 (+0.38%)
     
  • GBP/EUR

    1.1657
    +0.0001 (+0.01%)
     
  • GBP/USD

    1.2530
    +0.0019 (+0.15%)
     
  • Bitcoin GBP

    51,397.54
    +456.23 (+0.90%)
     
  • CMC Crypto 200

    1,390.08
    -6.45 (-0.46%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    83.74
    +0.17 (+0.20%)
     
  • GOLD FUTURES

    2,358.10
    +15.60 (+0.67%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,052.64
    +135.36 (+0.76%)
     
  • CAC 40

    8,042.79
    +26.14 (+0.33%)
     

What’s the Upside Potential of Nektar Therapeutics?

What’s the Upside Potential of Nektar Therapeutics?

Nektar Therapeutics (NKTR) is a San-Francisco-headquartered biopharmaceutical company with a focus on research. It is developing drug candidates that make use of Nektar’s advanced polymer conjugate technology platforms. Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating, while one analyst has given it a “hold” rating.